Appendix 4C - quarterly
Brisbane, July 22, 2016 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) today released its quarterly Appendix 4C - 4th Quarter Report.
Key points:
- Revenue of $2.283M for the quarter
- Positive quarter cash flow
- Cash increases to $13.7M
Chairman & CEO, Dr Mel Bridges said, "We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch," Dr Bridges added.
Anatara's Detac(TM) technology has potential to play a part as an alternative to traditional antibiotics to treat gastrointestinal diseases in farm (production) animals and humans.
To view the report, please visit:
http://abnnewswire.net/lnk/4ZRW2M8Q
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
